Back to Browse Journals » Clinical Ophthalmology » Volume 6

Improving quality of life in patients with end-stage age-related macular degeneration: focus on miniature ocular implants

Authors Singer MA, Amir N, Herro A, Porbandarwalla SS, Pollard J

Published 30 December 2011 Volume 2012:6 Pages 33—40


Review by Single-blind

Peer reviewer comments 4

Video presented by Michael Singer

Views: 453

Michael A Singer1, Nancy Amir2, Angela Herro3, Salman S Porbandarwalla3, Joseph Pollard1
1Medical Center Ophthalmology Associates, San Antonio, TX, USA; 2Santa Rosa Low Vision Clinic, San Antonio, TX, USA; 3University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

Abstract: Low vision devices in the past have been mainly extraocular. There are now four new devices in different stages of development and implementation that are currently available. Three of them, the Implantable Miniature Telescope (IMT, VisionCare Ophthalmic Technologies, Saratoga, CA), Intraocular Lens for Visually Impaired People (IOL-VIP, IOL-VIP System, Soleko, Pontecorvo, Italy), and Lipschitz Mirror Implant (LMI, Optolight Vision Technology, Herzlia, Israel) are implanted into the anterior segment while the Argus II (Second Sight Medical Products, Sylmar, CA) is implanted into the posterior segment. The goal of these devices is to increase the patient quality of life which has been measured by Visual Functioning Questionnaire (VFQ) scales. The IMT is the only device that has been shown to increase the VFQ score by seven points at 6 months compared to baseline. It is the only FDA-approved device in the US while the Argus has been approved in Europe. Each of these prosthetics has potential benefits for patients.

Keywords: IMT, IOL-VIP, LMI, Argus II

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

Fiber-optic triggered release of liposome in vivo: implication of personalized chemotherapy

Huang HL, Lu PH, Yang HC, Lee GD, Li HR, Liao KC

International Journal of Nanomedicine 2015, 10:5171-5185

Published Date: 14 August 2015

Nanosilver particles in medical applications: synthesis, performance, and toxicity

Ge L, Li Q, Wang M, Ouyang J, Li XJ, Xing MM

International Journal of Nanomedicine 2014, 9:2399-2407

Published Date: 16 May 2014

Management challenges arising from a traumatic 360 degree cyclodialysis cleft

Trikha S, Turnbull AMJ, Agrawal SS, Amerasinghe N, Kirwan JF

Clinical Ophthalmology 2012, 6:257-260

Published Date: 17 February 2012

Addition of a fixed combination of brinzolamide 1%/timolol 0.5% to prostaglandin monotherapy in patients with glaucoma or ocular hypertension

Lorenz K, Rosbach K, Matt A, Pfeiffer N

Clinical Ophthalmology 2011, 5:1745-1750

Published Date: 9 December 2011


Schneider EW, Johnson MW

Clinical Ophthalmology 2011, 5:1315-1316

Published Date: 16 September 2011

A case of recurrent bloody tears

Karslıoğlu Ş, Şimşek İB, Akbaba M

Clinical Ophthalmology 2011, 5:1067-1069

Published Date: 29 July 2011